Colloca Luana, Lopiano Leonardo, Lanotte Michele, Benedetti Fabrizio
University of Turin Medical School, Turin, Italy.
Lancet Neurol. 2004 Nov;3(11):679-84. doi: 10.1016/S1474-4422(04)00908-1.
The recent introduction of covert administration of treatment to biomedical research has produced some interesting results, with many clinical and ethical implications. Concealed treatment has been used in people with nervous system conditions including pain, anxiety, and Parkinson's disease. The main finding is that when the patient is completely unaware that a treatment is being given, the treatment is less effective than when it is given overtly in accordance with routine medical practice. The difference between open and hidden administrations is thought to represent the placebo component of the treatment, even though no placebo has been given. The decreased effectiveness of hidden treatments indicates that knowledge about a treatment affects outcome and highlights the importance of the patient-provider interaction. In addition, by use of covert administration, the efficacy of some treatments can be assessed without the use of a placebo and associated ethical issues.
近期将治疗的隐蔽给药引入生物医学研究产生了一些有趣的结果,具有诸多临床和伦理意义。隐蔽治疗已用于患有包括疼痛、焦虑和帕金森病在内的神经系统疾病的患者。主要发现是,当患者完全不知道正在接受治疗时,该治疗的效果不如按照常规医疗实践公开给药时有效。公开给药和隐蔽给药之间的差异被认为代表了治疗的安慰剂成分,尽管并未给予安慰剂。隐蔽治疗效果的降低表明对治疗的了解会影响结果,并突出了患者与提供者互动的重要性。此外,通过使用隐蔽给药,可以在不使用安慰剂及相关伦理问题的情况下评估某些治疗的疗效。